Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | HTR1B | P28222 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60535 | 0.75 | RAPGEF4 (0.43) | MEN1KMT2APOLBGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL3680590 | 0.73 | RAPGEF4 (0.41) | MEN1KMT2APOLBGAAALDH1A1 | |
| SCHEMBL28184328 | 0.73 | RAPGEF4 (0.41) | MEN1KMT2APOLBGAAALDH1A1 | |
| SCHEMBL9955356 | 0.72 | NMT1 (0.38) | MEN1KMT2APOLBALDH1A1PYCR1 | |
| SCHEMBL12159414 | 0.71 | NQO2 (0.38) | NQO2HTR1DHTR1BALDH1A1MAPK1 | |
| SCHEMBL1755248 | 0.71 | NQO2 (0.38) | NQO2HTR1DHTR1BALDH1A1CYP1A2 | |
| SCHEMBL13550083 | 0.71 | NQO2 (0.38) | POLBNQO2HTR1DHTR1BALDH1A1 | |
| SCHEMBL848904 | 0.71 | ALDH1A1 (0.40) | MEN1KMT2APOLBALDH1A1KDM4E | |
| SCHEMBL5797294 | 0.71 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL8565316 | 0.71 | CYP3A4 (0.50) | MEN1KMT2APOLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9346798-B2 | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-8981147-B2 | Diphosphine ligand and transition metal complex using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8981147-B2 | Diphosphine ligand and transition metal complex using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8981147-B2 | Diphosphine ligand and transition metal complex using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2015-02-26 | — | — | US | disclosed |
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009120826-A1 | 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | WYETH (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
| CN-101066975-A | Europium complex with visible light sensitized light emitting performance and its synthesis process | UNIV BEIJING (CN) | 2007-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | SCN5A, KCNH1, KCNQ5 | MEN1 2559/4885KMT2A 1801/4885POLB 4172/4885 |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | MEN1 4076/4885KMT2A 597/4885POLB 2234/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | MEN1 4076/4885KMT2A 597/4885POLB 2234/4885 |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | SEC63, SEC62, SEC22B | MEN1 2763/4885KMT2A 3676/4885POLB 4027/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | MEN1 658/4885KMT2A 1029/4885POLB 2366/4885 |
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | MVD, C5, C1S | MEN1 658/4885KMT2A 1029/4885POLB 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.